keyword
MENU ▼
Read by QxMD icon Read
search

cardio- oncology

keyword
https://www.readbyqxmd.com/read/30092977/imaging-in-cardio-oncology-where-are-we-and-where-should-we-be-going
#1
EDITORIAL
Richard M Steingart, Y Chandrashekhar, Thomas H Marwick
No abstract text is available yet for this article.
August 2018: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/30092969/contemporary-role-of-echocardiography-for-clinical-decision-making-in-patients-during-and-after-cancer-therapy
#2
REVIEW
Jennifer Liu, Jose Banchs, Negar Mousavi, Juan Carlos Plana, Marielle Scherrer-Crosbie, Paaladinesh Thavendiranathan, Ana Barac
Early recognition of cancer therapy-related cardiac dysfunction (CTRCD) provides an opportunity to mitigate cardiac injury and risk of developing late cardiac events. Echocardiography serves as the cornerstone in the detection and surveillance of CTRCD in patients during and after cancer therapy. Guidelines from professional societies and regulatory agencies have been published on approaches to surveillance, diagnosis, and treatment of CTRCD, although adoption as standard of care remains limited given the lack of evidence on the prognostic value of asymptomatic left ventricular (LV) dysfunction in the oncology population...
August 2018: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/30085070/cardio-oncology-services-rationale-organization-and-implementation-a-report-from-the-esc-cardio-oncology-council
#3
Patrizio Lancellotti, Thomas M Suter, Teresa López-Fernández, Maurizio Galderisi, Alexander R Lyon, Peter Van der Meer, Alain Cohen Solal, Jose-Luis Zamorano, Guy Jerusalem, Marie Moonen, Victor Aboyans, Jeroen J Bax, Riccardo Asteggiano
Aims: Anticancer therapies have extended the lives of millions of patients with malignancies, but for some this benefit is tempered by adverse cardiovascular (CV) effects. Cardiotoxicity may occur early or late after treatment initiation or termination. The extent of this cardiotoxicity is variable, depending on the type of drug used, combination with other drugs, mediastinal radiotherapy, the presence of CV risk factors, and comorbidities. A recent position paper from the European Society of Cardiology addressed the management of CV monitoring and management of patients treated for cancer...
August 6, 2018: European Heart Journal
https://www.readbyqxmd.com/read/30075937/emergence-of-cardio-oncology
#4
C G Nebigil, L Désaubry
Cardio-oncology is a new discipline that focuses on understanding, detection, monitoring and treating cardiovascular disease during and after cancer treatment. The development of this emerging field is based on an interdisciplinary collaboration between cardiology and oncology researchers and clinicians. Cardio-oncology aims at identifying how cancer therapies impact cardiovascular homeostasis, particular risk factors, diagnostic biomarkers and novel therapeutic approaches to help to effectively detect, prevent and cure the cardiotoxicity...
July 31, 2018: Annales Pharmaceutiques Françaises
https://www.readbyqxmd.com/read/30073443/cardio-oncology-a-new-and-developing-sector-of-research-and-therapy-in-the-field-of-cardiology
#5
REVIEW
Peggy M Kostakou, Nikos T Kouris, Vassilios S Kostopoulos, Dimitrios S Damaskos, Christoforos D Olympios
Cardio-oncology is a new field of interest in cardiology that focuses on the detection, monitoring, and treatment of cardiovascular disease occurring as a side effect of chemotherapy and radiotherapy. Both cancer treatment modalities can cause cardiac dysfunction, a major cause of morbidity and mortality in the oncologic population. It is necessary to periodically monitor cancer patients under treatment, especially those receiving anthracyclines and trastuzumab (monoclonal antibody), using mainly 3D echocardiography to calculate left ventricular ejection fraction and to estimate myocardial deformation...
August 2, 2018: Heart Failure Reviews
https://www.readbyqxmd.com/read/30054348/ers-eacts-statement-on-the-management-of-malignant-pleural-effusions
#6
Anna C Bibby, Patrick Dorn, Ioannis Psallidas, Jose M Porcel, Julius Janssen, Marios Froudarakis, Dragan Subotic, Phillippe Astoul, Peter Licht, Ralph Schmid, Arnaud Scherpereel, Najib M Rahman, Giuseppe Cardillo, Nick A Maskell
Malignant pleural effusions (MPE) are a common pathology, treated by respiratory physicians and thoracic surgeons alike. In recent years, several well-designed randomised clinical trials have been published that have changed the landscape of MPE management. The European Respiratory Society (ERS) and the European Association for Cardio-Thoracic Surgery (EACTS) established a multidisciplinary collaboration of clinicians with expertise in the management of MPE with the aim of producing a comprehensive review of the scientific literature...
July 2018: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/30051402/cardiovascular-implications-of-diabetes-metabolic-syndrome-thyroid-disease-and-cardio-oncology-in-women
#7
Marijana Tadic, Cesare Cuspidi, Dragan Vasic, Peter L M Kerkhof
Cardiovascular disease may be associated with several comorbidities, including diabetes mellitus, thyroid disorders, and the metabolic syndrome, which are predominantly observed in women and often starting at particular ages. In addition, common treatment options for carcinomas frequently seen in women may induce serious cardiotoxic effects. We review the scope of the problem, the pathophysiologic mechanisms involved, as well as the resulting abnormalities regarding cardiac structure and function as observed by using imaging techniques...
2018: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29976296/the-cardiologist-and-the-cancer-patient-challenges-to-cardio-oncology-or-onco-cardiology-and-call-to-action
#8
Tochi M Okwuosa, Nicole Prabhu, Hena Patel, Timothy Kuzel, Parameswaran Venugopal, Kim A Williams, Agne Paner
No abstract text is available yet for this article.
July 10, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29976295/neoplasia-and-the-heart-pathological-review-of-effects-with-clinical-and-radiological-correlation
#9
REVIEW
Joseph J Maleszewski, Melanie C Bois, John P Bois, Philip M Young, John M Stulak, Kyle W Klarich
The intersection of oncological and cardiovascular diseases is an increasingly recognized phenomenon. This recognition has led to the emergence of cardio-oncology as a true subspecialty. This field is not simply limited to primary cardiac tumors or complications of chemotherapeutic medications. Rather, it also encompasses metastatic cardiovascular complications and secondary cardiovascular effects of the underlying neoplasia. This review will broadly cover primary and metastatic cardiac neoplasms, as well as secondary cardiovascular effects of extracardiac neoplasia (e...
July 10, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29958808/editorial-commentary-update-on-cardio-oncology-novel-cancer-therapeutics-and-associated-cardiotoxicities
#10
EDITORIAL
Juan Lopez-Mattei, Peter Kim, Cezar Iliescu
No abstract text is available yet for this article.
June 19, 2018: Trends in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29938321/prevention-of-cardiotoxicities-with-traditional-and-novel-chemotherapeutic-agents
#11
REVIEW
Zarina Sharalaya, Patrick Collier
PURPOSE OF REVIEW: This review will discuss strategies to prevent cardiotoxicity associated with chemotherapeutics. Forty years ago, investigators identified dose-dependent cardiotoxicity related to anthracycline-based regimens. Over recent decades, the development of more selective, mechanism-based chemotherapeutics has been associated with both on-target and off-target adverse cardiovascular sequelae. RECENT FINDINGS: Strategies to prevent or attenuate cardiotoxicities include limitation of anthracycline dose, appropriate patient selection, referral/access to cardio-oncology programs, early recognition of cardiac side effects, active cardio-surveillance, cardio-protective medical therapy, treatment-specific concerns, and follow-up...
June 25, 2018: Current Heart Failure Reports
https://www.readbyqxmd.com/read/29931556/acute-coronary-syndrome-in-cancer-patients
#12
REVIEW
Begum Yetis Sayin, Mehmet Ali Oto
Cardiologists are seeing an increasing number of oncology patients every day, and acute coronary syndrome (ACS) is one of the problems patients encounter during follow-up. Cardio-oncology is the care of patients with cancer and cardiovascular disease, whether overt or occult, already established or acquired during treatment. Cardiovascular complications can occur acutely during or shortly after treatment and persist as long-term effects for months to years after treatment. As a delayed effect of cancer treatment, cardiovascular damage can occur months to years after the initial treatment...
June 22, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29929621/cardio-oncology-for-gennext-a-missing-piece-of-the-training-puzzle
#13
EDITORIAL
Sarju Ganatra, Salim S Hayek
No abstract text is available yet for this article.
June 26, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29910109/update-on-cardio-oncology-novel-cancer-therapeutics-and-associated-cardiotoxicities
#14
REVIEW
Avirup Guha, Merna Armanious, Michael G Fradley
There have been significant advances in the field of oncology leading to improved survival as a result of novel targeted and immunotherapies. Despite these improved outcomes, there is increased recognition of cardiotoxicities associated with these therapies that can lead to significant morbidity and mortality. As such, the field of cardio-oncology has seen significant growth over the last several years. In this review, we discuss recent advances in the field of cardio-oncology and provide a detailed discussion of the cardiovascular complications associated with novel cancer therapeutics including tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies...
June 8, 2018: Trends in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29909111/optimal-treatment-of-stage-b-heart-failure-in-cardio-oncology-the-promise-of-strain
#15
EDITORIAL
Ana Barac
No abstract text is available yet for this article.
June 8, 2018: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/29868614/interventional-cardio-oncology-adding-a-new-dimension-to-the-cardio-oncology-field
#16
Victor Y Liu, Ali M Agha, Juan Lopez-Mattei, Nicolas Palaskas, Peter Kim, Kara Thompson, Elie Mouhayar, Konstantinos Marmagkiolis, Saamir A Hassan, Kaveh Karimzad, Cezar A Iliescu
The management of cardiovascular disease in patients with active cancer presents a unique challenge in interventional cardiology. Cancer patients often suffer from significant comorbidities such as thrombocytopenia and coagulopathic and/or hypercoagulable states, which complicates invasive evaluation and can specifically be associated with an increased risk for vascular access complications. Furthermore, anticancer therapies cause injury to the vascular endothelium as well as the myocardium. Meanwhile, improvements in diagnosis and treatment of various cancers have contributed to an increase in overall survival rates in cancer patients...
2018: Frontiers in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29806680/-cardiotoxicity-of-anticancer-therapies-towards-the-implementation-of-cardio-oncology-units
#17
René Hameau, Luigi Gabrielli, Marcelo Garrido, Ana María Guzmán, Ignacio Retamal, María José Vacarezza, Douglas Greig, Mauricio Ocqueteau, César Sánchez, Marcela Pizarro, Alejandro Corvalán, Sergio Lavandero, Pablo F Castro, Gonzalo Martínez
Recently, we have witnessed major improvements in cancer treatment. Early diagnosis and development of new therapies have reduced cancer-related mortality. However, these new therapies, along with greater patient survival, are associated with an increase in untoward effects, particularly in the cardiovascular system. Although cardiotoxicity induced by oncologic treatments affects predominantly the myocardium, it can also involve other structures of the cardiovascular system, becoming one of the main causes of morbidity and mortality in those who survive cancer...
January 2018: Revista Médica de Chile
https://www.readbyqxmd.com/read/29802472/biomarker-discovery-in-cardio-oncology
#18
REVIEW
Anita Vohra, Aarti Asnani
PURPOSE OF REVIEW: In this article, we review current and emerging approaches to biomarker discovery to facilitate early diagnosis of cancer therapy-associated cardiovascular toxicity. RECENT FINDINGS: Although small studies have demonstrated an association between established biomarkers of cardiac injury (troponins and brain natriuretic peptide) and acute or subacute cardiotoxicity, there is insufficient evidence to support their use in routine clinical care. Preclinical studies to define the molecular mechanisms of cardiotoxicity, as well as the use of unbiased "omics" techniques in small patient cohorts, have yielded promising candidate biomarkers that have the potential to enrich current risk stratification algorithms...
May 25, 2018: Current Cardiology Reports
https://www.readbyqxmd.com/read/29783917/capecitabine-induced-myopericarditis-a-case-report-and-review-of-literature
#19
Sydney Saunders, Maria Anwar
Objective To describe a possible case of capecitabine-induced myopericarditis in a patient at the Cardio-Oncology Clinic in Calgary, AB. Design A literature search and adverse drug reaction assessment with the Naranjo tool was conducted. Results A 39-year-old male with recurrent locally advanced rectal adenocarcinoma presented two days after adjuvant treatment with capecitabine and oxaliplatin complaining of intermittent, severe interscapular pain. Based on symptoms, laboratory investigations, and imaging, the patient was diagnosed with acute myopericarditis...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29752960/assessment-of-herb-drug-synergy-to-combat-doxorubicin-induced-cardiotoxicity
#20
Aditi Jain, Vibha Rani
Aim Doxorubicin (Dox) is one of the most cardiotoxic anti-cancerous drug that is widely used for broad-range of cancers. There is an urgent need for developing cardio-oncological therapeutic interventions. Natural products having both anti-cancerous potential as well as cardioprotective effects may hold a great potential in this regard. Curcuma longa (an Indian herb) polyphenols including curcumin, and well known for its anti-oxidative and anti-cancerous potential was used in the present study for its synergistic effect on cancer cells and cardiomyocytes...
July 15, 2018: Life Sciences
keyword
keyword
163075
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"